Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx (ARGX) to $639 from $547 and keeps an Overweight rating on the shares. The firm’s initial read on Vyvgart’s chronic inflammatory demyelinating polyneuropathy revenue contribution during the quarter was too bullish, but the launch looks solid, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $670 from $610 at BofA
- Argenx price target raised to $606 from $497 at JMP Securities
- Argenx price target raised to $617 from $533 at H.C. Wainwright
- Argenx upgraded to Outperform from Market Perform at William Blair
- Argenx downgraded to Neutral from Outperform at Baird